The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
111 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $31,981,861 in first-year total cost, median $228,752.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-A (O1)]10
- Special Emphasis Panel[ZCA1 SRB-P (O1)]8
- Special Emphasis Panel[ZCA1 TCRB-V (M1)]8
- Special Emphasis Panel[ZCA1 SRB-1 (O1)]7
- Special Emphasis Panel[ZCA1 SRB-A (M1)]7
Most frequent institutions
- EMORY UNIVERSITY4
- UNIVERSITY OF CALIFORNIA, SAN DIEGO4
- UNIVERSITY OF TX MD ANDERSON CAN CTR4
- MAYO CLINIC ROCHESTER3
- OHIO STATE UNIVERSITY3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Chemo-neoepitopes as novel immunotherapy for triple negative breast cancer1R21CA241044-01A1 | IONOV, YURIJMANDOIU, IONSRIVASTAVA, PRAMOD K.ZELIKOVSKIY, ALEKSANDR | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $466,702 | ZCA1 |
| 2021 | Chemical manipulation of creatine kinases to treat acute myeloid leukemia1R21CA259739-01 | CHOUCHANI, EDWARD THOMAS | DANA-FARBER CANCER INST, MA | $450,655 | ZCA1 |
| 2021 | Identifying neuroblastoma drivers and bringing them to the clinic1R21CA259771-01 | SKAPEK, STEPHEN XXU, LIN | UT SOUTHWESTERN MEDICAL CENTER, TX | $437,425 | ZCA1 |
| 2021 | Role of LMPTP in Prostate Cancer1R21CA245621-01A1 | STANFORD, STEPHANIE | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $421,889 | ZCA1 |
| 2021 | Contribution of Epigenome to PRKCI-Driven High-Grade Serous Ovarian Cancer1R21CA256278-01 | RAI, KUNAL | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $416,543 | ZCA1 |
| 2021 | Characterization and targeting the CXCR2-STAT-1/3 axis in metastatic Ewing sarcoma1R21CA260331-01 | DASGUPTA, ATREYIYUSTEIN, JASON | BAYLOR COLLEGE OF MEDICINE, TX | $412,516 | ZCA1 |
| 2021 | HULLK, a novel lncRNA that functions as a targetable oncogene in PCa1R21CA259716-01 | GIOELI, DANIEL G | UNIVERSITY OF VIRGINIA, VA | $410,710 | ZCA1 |
| 2021 | Improving response to immunotherapy by genistein and antiestrogens1R21CA256428-01 | HILAKIVI-CLARKE, LEENA A. | UNIVERSITY OF MINNESOTA, MN | $407,663 | ZCA1 |
| 2021 | Identification of serum protein biomarkers by profiling N-glycoproteomes of patient-derived xenografts of clear cell renal cell carcinoma1R21CA256271-01 | BROOKS, JAMES D.PITTERI, SHARON | STANFORD UNIVERSITY, CA | $405,619 | ZCA1 |
| 2021 | Evaluating a Novel Autophagy Inhibitor in KRAS-Driven Lung Cancer1R21CA252430-01A1 | MACKEIGAN, JEFFREY PAUL | MICHIGAN STATE UNIVERSITY, MI | $402,401 | ZCA1 |
| 2021 | Targeting BUB 1 for radio- and immuno-sensitization of Triple Negative Breast Cancer (TNBC)1R21CA252010-01A1 | GREEN, MICHAEL DANIELNYATI, SHYAM | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $401,117 | ZCA1 |
| 2021 | Identification of TR4 Modulators for Treatment of Cushing Disease.1R21CA259943-01 | HEANEY, ANTHONY P | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $401,115 | ZCA1 |
| 2021 | Shifting the immune infiltrates in osteosarcoma lung metastases with locally targeted CSF-1Ris for combination therapies1R21CA259969-01 | DA ROCHA, SANDRO R. P. | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $399,187 | ZCA1 |
| 2021 | Video Intervention to Address Pre-Test Patient Education for Tumor Genomic Testing1R21CA259985-01 | SENTER-JAMIESON, LEIGHASTOVER, DANIEL G. | OHIO STATE UNIVERSITY, OH | $395,878 | ZCA1 |
| 2021 | Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell Lymphoma1R21CA259694-01 | GREEN, MICHAEL RICHARDSTRATI, PAOLO | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $378,675 | ZCA1 |
| 2021 | Novel Treatment Strategies for Cancer1R21CA259440-01 | THOMAS, GEORGE VICTOR | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $287,980 | ZCA1 |
| 2021 | Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-02401R21CA256384-01 | NIXON, ANDREW B.SECORD, ANGELES ALVAREZ | DUKE UNIVERSITY, NC | $267,952 | ZCA1 |
| 2021 | RNASEH2B loss to predict response to PARP inhibitor in prostate cancer1R21CA252578-01A1 | JIA, LI | BRIGHAM AND WOMEN'S HOSPITAL, MA | $251,048 | ZCA1 |
| 2021 | Elucidating the role of the SWI/SNF complex in mediating hormone therapy resistance in breast cancer1R21CA252530-01A1 | TOSKA, ENEDA | JOHNS HOPKINS UNIVERSITY, MD | $249,718 | ZCA1 |
| 2021 | Neoadjuvant PD-1 blockade in mismatch repair deficient rectal cancer1R21CA252519-01A1 | CERCEK, ANDREA | SLOAN-KETTERING INST CAN RESEARCH, NY | $248,243 | ZCA1 |
| 2021 | Synthetic rocaglates as promising therapeutic agents for aggressive hematological malignancies1R21CA245448-01A1 | FU, KAI | ROSWELL PARK CANCER INSTITUTE CORP, NY | $247,135 | ZCA1 |
| 2021 | Low-Field High-Performance MRI for Screening Clinically Significant Prostate Cancer1R21CA256324-01 | CHANDARANA, HERSH | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $237,724 | ZCA1 |
| 2021 | RESISTANCE AND RESPONSE SIGNALING TO PARP1 INHIBITORS IN OVARIAN CANCER1R21CA252373-01A1 | MONTEIRO, ALVARO NRIX, UWE | H. LEE MOFFITT CANCER CTR & RES INST, FL | $230,992 | ZCA1 |
| 2021 | Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa Study)1R21CA255835-01 | ADEBAMOWO, CLEMENT ADEBAYO | UNIVERSITY OF MARYLAND BALTIMORE, MD | $228,752 | ZCA1 |
| 2021 | Function of V-ATPases in Breast Cancer Metastasis1R21CA245172-01A1 | FORGAC, MICHAEL DKUPERWASSER, CHARLOTTE | TUFTS UNIVERSITY BOSTON, MA | $227,766 | ZCA1 |
| 2021 | Sensitivity of Abi1/Pten null tumors to taxane and anti-androgen receptor therapy1R21CA260381-01 | KOTULA, LESZEK | UPSTATE MEDICAL UNIVERSITY, NY | $227,205 | ZCA1 |
| 2021 | Understanding and Targeting Tiam1 in Cancer1R21CA254968-01 | MANOR, DANNY | CASE WESTERN RESERVE UNIVERSITY, OH | $225,803 | ZCA1 |
| 2021 | PD-L1 inhibition promotes type I interferon responses, enhancing chemotherapy-induced cytotoxicity in cancer cells1R21CA252387-01A1 | CHEON, HYEONJOO | CLEVELAND CLINIC LERNER COM-CWRU, OH | $225,803 | ZCA1 |
| 2021 | Near-IR Ratiometric Fluorescence Probes for Assessing Cargo Delivery to Prostate Tumors1R21CA256382-01 | BERKMAN, CLIFFORDCAROMILE, LESLIE ANN | WASHINGTON STATE UNIVERSITY, WA | $224,845 | ZCA1 |
| 2021 | Genetic Biomarkers for Risk of CLL Progression among high-count MBLs1R21CA256648-01 | KLEINSTERN, GEFFENSLAGER, SUSAN L | MAYO CLINIC ROCHESTER, MN | $223,557 | ZCA1 |
| 2021 | Rapid evaluation of immunotherapy regimens in ex vivo human pancreatic tumor slice cultures.1R21CA255291-01 | MUNSHI, HIDAYATULLAH G. | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $222,297 | ZCA1 |
| 2021 | The impact of exposure to allergic inflammation on esophageal carcinogenesis1R21CA256465-01 | WHELAN, KELLY A | TEMPLE UNIV OF THE COMMONWEALTH, PA | $222,296 | ZCA1 |
| 2021 | Exploration of Novel Mutation Biomarkers to Repurpose EGFRi for Mutant KRAS Colorectal Cancer1R21CA252436-01A1 | FLOROU, VAIA | UNIVERSITY OF UTAH, UT | $221,771 | ZCA1 |
| 2021 | Identification of Novel Regulators of Natural Killer Cell Activity1R21CA241006-01A1 | KAUFMAN, DAN S. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $221,186 | ZCA1 |
| 2021 | Genomic analysis of prostate tumor heterogeneity in metastasis1R21CA256375-01 | MORENO, CARLOS SANCHEZ | EMORY UNIVERSITY, GA | $218,966 | ZCA1 |
| 2021 | Re-purposing beta-blockers to improve chemotherapy response1R21CA245667-01A1 | ROWAT, AMY C | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $218,790 | ZCA1 |
| 2021 | Targeting the metabolic vulnerabilities of patient-derived drug resistant tumors1R21CA256546-01 | AVANTAGGIATI, MARIA L | GEORGETOWN UNIVERSITY, DC | $218,790 | ZCA1 |
| 2021 | The Lung Tumor Microenvironment: Role of Resident Pulmonary Vascular Progenitor Cells in Cancer Progression and Metastasis1R21CA255246-01 | NEMENOFF, RAPHAEL A.WEISER-EVANS, MARY CM. | UNIVERSITY OF COLORADO DENVER, CO | $218,089 | ZCA1 |
| 2021 | Targeting USP10 to regulate the DNA damage response in NSCLC1R21CA256423-01 | BEPLER, GEROLDZHANG, XIAOHONG MARY | WAYNE STATE UNIVERSITY, MI | $215,985 | ZCA1 |
| 2021 | Repurposing Sulfasalazine in a Two-Arm Phase Two Double-Blind Randomized Clinical Trial for the Adjunct Management of Breast Cancer-Induced Bone Pain1R21CA245411-01A1 | IBRAHIM, MOHAB M | UNIVERSITY OF ARIZONA, AZ | $215,284 | ZCA1 |
| 2021 | Mediators of Pancreatic Cancer-Associated Cachexia1R21CA256409-01 | CRUZ-MONSERRATE, ZOBEIDA | OHIO STATE UNIVERSITY, OH | $214,496 | ZCA1 |
| 2021 | Role of cDC2 subsets in host protection and CD4T cell responses in melanoma1R21CA259541-01 | KUMAMOTO, YOSUKE | RBHS-NEW JERSEY MEDICAL SCHOOL, NJ | $214,012 | ZCA1 |
| 2021 | Use of Ly6K specific CAR T-cells to treat primary and metastatic triple negative breast cancer1R21CA256424-01 | UPADHYAY, GEETA | HENRY M. JACKSON FDN FOR THE ADV MIL/MED, MD | $213,876 | ZCA1 |
| 2021 | A large animal model to elucidate the role of LGR5 stem cells in cancer1R21CA256001-01 | PIEDRAHITA, JORGE A | NORTH CAROLINA STATE UNIVERSITY RALEIGH, NC | $213,180 | ZCA1 |
| 2021 | Neoadjuvant Stroma Modification in Pancreatic Cancer1R21CA252535-01A1 | ASTSATUROV, IGORDOTAN, EFRAT | RESEARCH INST OF FOX CHASE CAN CTR, PA | $210,508 | ZCA1 |
| 2021 | Ribonucleotide Reductase in Hepatoblastoma Progression and Drug Resistance1R21CA256464-01 | ZHU, LIQIN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $209,791 | ZCA1 |
| 2021 | Cerebrospinal fluid derived circulating tumor DNA as a clinically relevant biomarker in medulloblastoma1R21CA256386-01 | NORTHCOTT, PAUL | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $209,791 | ZCA1 |
| 2021 | Fluorescence Molecular In Vivo Liquid Biopsy of Circulating Tumor Cells1R21CA246413-01A1 | NIEDRE, MARK JONATHAN | NORTHEASTERN UNIVERSITY, MA | $209,534 | ZCA1 |
| 2021 | A Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer1R21CA259808-01 | MCDONALD, ANDREW M | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $208,271 | ZCA1 |
| 2021 | Patient-derived organoids reveal rectal cancers develop radiosensitivity1R21CA245636-01A1 | KOLESNICK, RICHARD N | SLOAN-KETTERING INST CAN RESEARCH, NY | $206,869 | ZCA1 |
| 2021 | Identifying primary targets of bumped kinase inhibitor derived compounds to improve utility as therapy for castration resistant prostate cancer1R21CA255830-01 | UO, TAKUMA | UNIVERSITY OF WASHINGTON, WA | $206,284 | ZCA1 |
| 2021 | Determining the role of gas metabolite in response to immunotherapy1R21CA256720-01 | WEGIEL, BARBARA | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $204,531 | ZCA1 |
| 2021 | DEHART: Dose-Escalated Hypofractionated Adaptive Radiation Therapy for Head and Neck Cancers1R21CA256144-01 | AWAN, MUSADDIQ | MEDICAL COLLEGE OF WISCONSIN, WI | $201,960 | ZCA1 |
| 2021 | Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma1R21CA259236-01 | ORME, JACOBPARK, SEAN S | MAYO CLINIC ROCHESTER, MN | $201,871 | ZCA1 |
| 2021 | Single-Cell Transcriptome & Effect of Immune Checkpoint Therapy on Kaposi Sarcoma1R21CA257493-01 | RATNER, LEERAUCH, DANIEL ARTHUR | WASHINGTON UNIVERSITY, MO | $196,875 | ZCA1 |
| 2021 | ROS Targeted Therapy for Lethal Prostate Cancer1R21CA256419-01 | WANG, RUOXIANGZHANG, YI | CEDARS-SINAI MEDICAL CENTER, CA | $195,181 | ZCA1 |
| 2021 | Human Donor Stem/Progenitor Cells with Dual Gene Editing (CD33 and CLL-1) Enable "Two Hit" targeting of Acute Myeloid Leukemia"1R21CA256461-01 | ALI, ABDULLAH M | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $189,338 | ZCA1 |
| 2021 | Inhibition of CaMKK2 sensitizes rectal cancers to radiation therapy1R21CA256414-01 | LEE, CHANG-LUNGROPER, JATIN | DUKE UNIVERSITY, NC | $188,169 | ZCA1 |
| 2021 | Breast cancer virotherapy1R21CA252027-01A1 | HE, BIN | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $186,883 | ZCA1 |
| 2021 | Body composition and chemotherapy toxicity among women being treated for breast cancer1R21CA259790-01 | ROBIEN, KIMBERLY Z | GEORGE WASHINGTON UNIVERSITY, DC | $186,416 | ZCA1 |
| 2021 | Redefining hemophagocytic lymphohistiocytosis in hematologic malignancies1R21CA256390-01 | JORDAN, MICHAEL | CINCINNATI CHILDRENS HOSP MED CTR, OH | $185,831 | ZCA1 |
| 2021 | Investigating Mechanisms of Hyperprogression on Anti-PD-1 Immunotherapy1R21CA256360-01 | SHARABI, ANDREW B. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $184,371 | ZCA1 |
| 2021 | Role of Protein Kinase C Mutations in Adult T-Cell Leukemia1R21CA255095-01 | RATNER, LEERAUCH, DANIEL ARTHUR | WASHINGTON UNIVERSITY, MO | $184,078 | ZCA1 |
| 2021 | Interaction of HTLV-1 Tax & Hbz in Transformation1R21CA252869-01A1 | RATNER, LEERAUCH, DANIEL ARTHUR | WASHINGTON UNIVERSITY, MO | $184,078 | ZCA1 |
| 2021 | PET Imaging Agents for Protoporphyrin IX1R21CA259935-01 | GOODMAN, MARK MYRONMAO, HUI | EMORY UNIVERSITY, GA | $182,568 | ZCA1 |
| 2021 | Understanding PD-L1/L2 protein regulation, detection and signaling to predict melanoma therapeutic sensitivity1R21CA255837-01 | LO, ROGER S | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $182,325 | ZCA1 |
| 2021 | Synthetic lethality in leukemic stem cells in juvenile myelomonocytic leukemia1R21CA255831-01 | QU, CHENG-KUI | EMORY UNIVERSITY, GA | $182,325 | ZCA1 |
| 2021 | Exploiting Urine Derived DNA for the Assessment of Bladder Cancer using High Accuracy Sequencing1R21CA259780-01 | KENNEDY, SCOTT ROBERT | UNIVERSITY OF WASHINGTON, WA | $181,741 | ZCA1 |
| 2021 | Re-engineered Mitochondrially Targeted p53 Gene Therapy in Liver Cancer1R21CA241015-01A1 | LIM, CAROL S. | UNIVERSITY OF UTAH, UT | $178,234 | ZCA1 |
| 2021 | Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly1R21CA252579-01A1 | KWON, GLEN S.PONIK, SUZANNE MARIE | UNIVERSITY OF WISCONSIN-MADISON, WI | $176,980 | ZCA1 |
| 2021 | Usurping TIGIT and CD73 activities with responsive, genetically-engineered NK cells as immunotherapy for glioblastoma1R21CA256413-01 | MATOSEVIC, SANDRO | PURDUE UNIVERSITY, IN | $175,849 | ZCA1 |
| 2021 | Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging.1R21CA256280-01 | SCHUSTER, DAVID MICHAEL | EMORY UNIVERSITY, GA | $169,125 | ZCA1 |
| 2021 | Optimizing NK Cell-Engaging Bispecific Antibody Therapy Targeting CD331R21CA259779-01 | WALTER, ROLAND BRUNO | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $163,219 | ZCA1 |
| 2021 | Exploratory clinical trial of topical Imiquimod 5% cream as window-of-opportunity monotherapy for early-stage oral cancer1R21CA252441-01A1 | CARVAJAL, RICHARDYOON, ANGELA JIYEON | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $126,755 | ZCA1 |
| 2021 | Eliminating B Cell Precursor Acute Lymphoblastic Leukemia by Targeting the Uniquely Specific Pre-B Cell Receptor1R21CA256319-01 | TJOELKER, LARRY W. | PASCAL BIOSCIENCES US, INC., WA | $116,875 | ZCA1 |
| 2021 | Faithful mouse modeling of human lung cancer1R21CA259706-01 | XIAO, GUTIAN | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $16,770 | ZCA1 |
| 2020 | Targeting CD5 on Tumor-associated T and B cells to improve PD-1 blockade in Breast Cancer1R21CA241283-01A1 | ZHANG, CHUNYAN | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $452,540 | ZCA1 |
| 2020 | Targeting Cell Cycle Plasticity in Pancreatic Ductal Adenocarcinoma1R21CA252585-01 | HUAN, CHONGMINKNUDSEN, ERIK | SUNY DOWNSTATE MEDICAL CENTER, NY | $438,275 | ZCA1 |
| 2020 | 3D co-culture system to characterize and target leukemia stem cells1R21CA245454-01A1 | GUZMAN, MONICA L | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $435,827 | ZCA1 |
| 2020 | Targeting the senescence-associated secretory phenotype as an adjuvant therapy to prevent breast cancer progression1R21CA246416-01A1 | DAVID, GREGORY | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $435,827 | ZCA1 |
| 2020 | Augmenting Anti-Tumor Immunity Using Radiation in the Setting of DNA Repair Defects1R21CA252411-01 | SAWAKUCHI, GABRIEL OLIVEIRASHAITELMAN, SIMONA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $431,284 | ZCA1 |
| 2020 | "Exploration of Human Parathyroid Cellular Organization and Function"1R21CA240660-01A1 | KRAUSE, DIANE S | YALE UNIVERSITY, CT | $430,686 | ZCA1 |
| 2020 | Development of novel CXCR5 PET Imaging probe for Angioimmunoblastic T-cell Lymphoma1R21CA252587-01 | CAI, ZHENGXIN | YALE UNIVERSITY, CT | $430,685 | ZCA1 |
| 2020 | Exploring enzyme-instructed self-assembly (EISA) for targeting osteoblastic metastasis of prostate cancer1R21CA252364-01 | HSIEH, JER-TSONGXU, BING | BRANDEIS UNIVERSITY, MA | $430,496 | ZCA1 |
| 2020 | Anti-Sox2 immunotherapy to prevent multiple myeloma relapse1R21CA238108-01A1 | GARFALL, ALFRED L. | UNIVERSITY OF PENNSYLVANIA, PA | $423,948 | ZCA1 |
| 2020 | Developing bispecific CAR Ts for treating AML1R21CA252558-01 | HUA, XIANXIN | UNIVERSITY OF PENNSYLVANIA, PA | $417,244 | ZCA1 |
| 2020 | Identifying Actionable Signatures of Duodenopancreatic Neuroendocrine Tumor Progression in MEN11R21CA252426-01 | HANASH, SAMIR M | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $416,543 | ZCA1 |
| 2020 | Engineering ERK-specificity for cancer suicide gene therapy1R21CA252576-01 | LAZZARA, MATTHEW JPUROW, BENJAMIN W. | UNIVERSITY OF VIRGINIA, VA | $415,245 | ZCA1 |
| 2020 | MicroRNA Targeted Therapeutic Approach for Pediatric High-Grade Glioma1R21CA252370-01 | YAMADA, TOHRU | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $411,143 | ZCA1 |
| 2020 | Blood-based biomarker of therapeutic efficacy for mesothelioma1R21CA251923-01 | MANSFIELD, AARON SCOTT | MAYO CLINIC ROCHESTER, MN | $408,829 | ZCA1 |
| 2020 | A Novel ULK1 Pathway as a New Therapeutic Target in Melanoma1R21CA245447-01A1 | NORA VAZ SALEIRO, DIANA | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $408,596 | ZCA1 |
| 2020 | Development of Next-Generation Precision Medicine RNAi Therapeutics to Treat AML1R21CA252511-01 | DOWDY, STEVEN F | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $405,557 | ZCA1 |
| 2020 | Innovative Cell Therapy for Pediatric Acute Myeloid Leukemia1R21CA245468-01A1 | RONCAROLO, MARIA GRAZIA | STANFORD UNIVERSITY, CA | $405,486 | ZCA1 |
| 2020 | Smoking carcinogen-induced initiation of pancreatic cancer1R21CA244167-01A1 | STORZ, PETER | MAYO CLINIC JACKSONVILLE, FL | $402,400 | ZCA1 |
| 2020 | Defining HPV integration sites of unknown significance in invasive cervical cancer1R21CA241013-01A1 | RADER, JANET S. | MEDICAL COLLEGE OF WISCONSIN, WI | $401,115 | ZCA1 |
| 2020 | Interruption of cholesterol metabolism and replication stress response in cancer therapy1R21CA241242-01A1 | ZHANG, JUNRAN | OHIO STATE UNIVERSITY, OH | $401,115 | ZCA1 |
| 2020 | Developing non-human primate models for ovarian cancer1R21CA234804-01A1 | PATANKAR, MANISH S | UNIVERSITY OF WISCONSIN-MADISON, WI | $399,185 | ZCA1 |
| 2020 | Regulation of P-Body Formation and mRNA Decapping in Cancer: Control by AKT and Pim Kinase Phosphorylation of EDC31R21CA241010-01A1 | OKUMURA, KOICHI | UNIVERSITY OF ARIZONA, AZ | $394,690 | ZCA1 |
| 2020 | PROTACs for pancreatic cancer therapy1R21CA251151-01 | NATARAJAN, AMARNATH (AMAR) | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $393,400 | ZCA1 |
| 2020 | Regulation of Death Receptor 5 folding and apoptotic signaling by AGR21R21CA252400-01 | LAW, BRIAN K. | UNIVERSITY OF FLORIDA, FL | $388,757 | ZCA1 |
| 2020 | Fluorescence lifetime technique for intraoperative identification of IDH mutations in brain cancer1R21CA252510-01 | BLOCH, ORINMARCU, LAURA | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $386,565 | ZCA1 |
| 2020 | Imaging of alterations in SSTR2 expression with histone deacetylase (HDAC) inhibitors treatment for neuroendocrine tumors1R21CA245580-01A1 | JASKULA-SZTUL, RENATALAPI, SUZANNE ELIZABETH | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $381,830 | ZCA1 |
| 2020 | GBM Avatar Screening Paradigm for Rational Pharmacokinomic Glioma Therapy1R21CA252382-01 | WILLEY, CHRISTOPHER D | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $381,264 | ZCA1 |
| 2020 | Proteomic Characterization of Genomically Complex Sarcomas1R21CA251992-01 | ROEHRL, MICHAEL H. A. | SLOAN-KETTERING INST CAN RESEARCH, NY | $381,085 | ZCA1 |
| 2020 | Fusing the commercial drugs triapine and deferasirox to create Ti(IV) anticancer compounds that inhibit the bioavailability of iron1R21CA240997-01A1 | TINOCO, ARTHUR DAVID | UNIVERSITY OF PUERTO RICO RIO PIEDRAS, PR | $370,325 | ZCA1 |
| 2020 | Virtual Histology of the Bladder Wall for Bladder Cancer Staging1R21CA252590-01 | MARANCHIE, JODI KATHLEENTYAGI, PRADEEP | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $326,485 | ZCA1 |
| 2020 | Targeting ERK5 for Colorectal Cancer Therapy1R21CA244691-01A1 | POWIS, GARTH | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $273,488 | ZCA1 |
| 2020 | Renal Cell Carcinoma Surveillance by Immuno-Lipoplex Nanoparticle Platform1R21CA252344-01 | JIANG, WENYANG, ZHAOGANG | UT SOUTHWESTERN MEDICAL CENTER, TX | $229,134 | ZCA1 |
| 2020 | Lysosomal TRP channels in metastatic melanoma1R21CA252428-01 | DU, WANLU | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $218,790 | ZCA1 |
| 2020 | Development of a noninvasive, rapid and affordable method for early detection of colorectal cancer1R21CA245651-01A1 | OSKERITZIAN, CAROLE A | UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA, SC | $208,973 | ZCA1 |
| 2020 | Nanoparticle delivered miR-489 rejuvenates anthracycline-based chemotherapy1R21CA252360-01 | CHEN, HEXINXU, PEISHENG | UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA, SC | $180,017 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.